Scil Proteins GmbH

20 articles about Scil Proteins GmbH

• UV-Cap GmbH & Co KG Acquires Scil Proteins GmbH, Company Will Be Renamed Navigo Proteins

  2/3/2017

• ITM And Scil Proteins GmbH Announce New Partnership For Targeted Radio Conjugates

  3/24/2016

• Scil Proteins GmbH Production To Join WACKER Creating Leading Microbial-Based Biopharmaceutical Manufacturer

  11/12/2013

• Scil Proteins GmbH: Novel Recombinant Human Thrombin Provided in Innovative Stabilized Formulation

  10/31/2013

• Scil Proteins GmbH Obtains European Medicines Agency Approval for Commercial Production of Reteplase

  10/22/2012

• Rainer-Rudolph-Prizes Awarded to Three Young and Talented Protein Scientists

  10/15/2012

• Scil Proteins GmbH Named Winner of the "Großer Preis des Mittelstandes" Competition

  9/25/2012

• Scil Proteins GmbH, Ono Pharmaceutical Company, Ltd. Establish Affilin Therapeutics Discovery and Development Collaboration

  5/15/2012

• Scil Proteins GmbH Establishes Business Development Infrastructure in North America

  3/14/2012

• Scil Proteins GmbH to Manufacture Reteplase for Actavis

  1/17/2012

• Scil Proteins GmbH Appoints Frank Ubags as Chief Operating Officer

  12/6/2011

• Scil Proteins GmbH Successfully Completes Manufacture of Recombinant Protein Candidate for Lundbeck Inc.

  11/15/2011

• Scil Proteins GmbH Signs Research Collaboration with the Martin Luther-University Halle-Wittenberg for Gastrointestinal Tumors

  8/16/2011

• Scil Proteins GmbH Signs Licensing and Pre Manufacturing Agreement with Anabasis/Dompé for Eye Indications

  6/30/2011

• Scil Proteins GmbH Receives €700K Research Grant from Investitionsbank Sachsen Anhalt

  4/7/2011

• Scil Proteins GmbH Raises Financing of Euro 24 Million (US$33.1M)

  2/2/2011

• Scil Proteins GmbH Appoints Advisory Board

  8/11/2010

• Scil Proteins GmbH Affilin(R) Drug Discovery Platform Validated in Animals

  6/23/2010

• Scil Proteins GmbH Closes Manufacturing Deal for Reteplase with Roche

  6/24/2008

• Scil Proteins GmbH And Cambridge Antibody Technology Group PLC Sign Cross-Licence Agreement In The Field Of Affilin Technology And Ribosome Display

  7/19/2006